Mantle Cell Lymphoma Excellence Forum

Mantle Cell Lymphoma

Excellence Forum

Leaders in the field sharing authoritative insights and institutional best practices.

Videos

Study Profiles T-Cell Subpopulations Based on Spatial Proteome in MCL

04/18/2022

Lavanya Lokhande, PhD, discusses results from a study, presented at the AACR Annual Meeting, which investigated T-cell subpopulations profiled by spatial proteome among patients with MCL.

Lavanya Lokhande, PhD, discusses...

04/18/2022

Oncology

Videos

Loss of GTPase RhoA Impairs Lenalidomide Activity in MCL

04/18/2022

Gaël Roué, PhD, highlights a study providing insight into how the loss of the small GTPase RhoA enhances lymphomagenesis and impairs the activity of lenalidomide in patients with MCL.

Gaël Roué, PhD, highlights a...

04/18/2022

Oncology

Videos

Impact of CD163-Positive Cells on MCL Development and Treatment Response

04/13/2022

A study presented at the AACR Annual Meeting demonstrates that spatial localization within the MCL tumor affects the expression of CD163-positive macrophages and identifies possible targetable markers.

A study presented at the AACR...

04/13/2022

Oncology

Videos

Dr Aroldi Overviews CD24 ‘Don’t Eat Me’ Signal as a Potential Immunotherapeutic Target for MCL

03/29/2022

Andrea Aroldi, MD, overviews the CD24 ‘don’t eat me’ signal immune checkpoint blockade as a potential immunotherapeutic target for MCL, presented at ASH 2021.

Andrea Aroldi, MD, overviews the...

03/29/2022

Oncology

Conference Insider

Dr Martin Discusses How to Approach MCL

03/23/2022

Emily Bader

Peter Martin, MD, discusses how to approach MCL, including what’s been learned so far and what’s to be expected, at the virtual Great Debates & Updates in Hematologic Malignancies.

Peter Martin, MD, discusses how...

03/23/2022

Oncology

Videos

Dr Lee Reviews Cirmtuzumab and Ibrutinib in MCL/CLL

03/02/2022

Hun Ju Lee, MD, reviews a phase 1b/2 study of cirmtuzumab and ibrutinib for patients with MCL or CLL.

Hun Ju Lee, MD, reviews a phase...

03/02/2022

Oncology

Videos

Dr Beitinjaneh Highlights Brexucabtagene Autoleucel for R/R MCL

02/10/2022

Amer Beitinjaneh, MD, MPH, MSc, highlights a multicenter retrospective study on brexucabtagene autoleucel, which was approved by the FDA in July 2020 and demonstrates encouraging safety and efficacy, for R/R MCL.

Amer Beitinjaneh, MD, MPH, MSc,...

02/10/2022

Oncology

Videos

Dr Kumar Highlights Safety, Efficacy of Obinutuzumab-Based Triplet Regimen for TP35-Mutant MCL

02/04/2022

Anita Kumar, MD, highlights preliminary safety and efficacy data from a phase 2 study on zanubrutinib, obinutuzumab, and venetoclax for untreated patients with MCL expressing a TP53 mutation.

Anita Kumar, MD, highlights...

02/04/2022

Oncology

Podcasts

Dr Melani Shares Impressive Results of the ViPOR Regimen for MCL

02/02/2022

Dr Melani discusses results and safety outcomes of the ViPOR trial with venetoclax, ibrutinib, prednisone, obinutuzumab, and lenalidomide to treat R/R and untreated MCL, presented at the 2021 Annual ASH Meeting.

Dr Melani discusses results and...

02/02/2022

Oncology

Videos

Glofitamab Step-Up Dosing Induces High Response Rates in MCL

01/19/2022

Tycel Phillips, MD, highlights how glofitamab step-up dosing induces high response rates in patients with R/R MCL that didn't respond to BTKi therapy. These data were presented at ASH 2021.

Tycel Phillips, MD, highlights...

01/19/2022

Oncology

Recent News

Conference Insider

Dr Martin Discusses How to Approach MCL

03/23/2022

Emily Bader

Peter Martin, MD, discusses how to approach MCL, including what’s been learned so far and what’s to be expected, at the virtual Great Debates & Updates in Hematologic Malignancies.

Peter Martin, MD, discusses how...

03/23/2022

Oncology

News

Laparoscopic Hemihepatectomy vs Open Hemihepatectomy Among Patients With Primary or Metastatic Liver Tumors

05/17/2024

Stephanie Holland

Results from the ORANGE II PLUS trial demonstrated that a minimally invasive, laparoscopic approach to hemihepatectomy shortened time to functional recovery compared to open, major hemihepatectomy among patients with primary or metastatic...

Results from the ORANGE II PLUS...

05/17/2024

Oncology

News

FDA Grants Accelerated Approval to Tarlatamab for Patients With Extensive-Stage Small Cell Lung Cancer

05/17/2024

Stephanie Holland

Based on results from the DELLphi-301 trial, the FDA has granted accelerated approval to tarlatamab for patients with extensive-stage small cell lung cancer.

Based on results from the...

05/17/2024

Oncology

News

FDA Approves Lisocabtagene Maraleucel for Adult Patients With R/R Follicular Lymphoma

05/16/2024

Amber Denham

The US Food and Drug Administration granted accelerated approval to lisocabtagene maraleucel for adult patients with relapsed or refractory follicular lymphoma who have received 2 or more prior lines of systemic therapy.

The US Food and Drug...

05/16/2024

Oncology

News

No Improvement From Adjuvant Radiotherapy Post-Prostatectomy for Patients With Prostate Cancer At Risk of Recurrence

05/14/2024

Stephanie Holland

According to long-term results from the RADICALS-RT study, adjuvant radiotherapy does not meaningfully improve disease control and increases the risk of urinary and bowel morbidities among patients with prostate cancer at risk of recurrence...

According to long-term results...

05/14/2024

Oncology

News

Datopotamab Deruxtecan Shows Promising Activity, Safety Among Heavily Pretreated Patients With HR-Positive, HER2-Negative, or Triple-Negative Breast Cancer

05/14/2024

Stephanie Holland

According to results from the ongoing phase 1 TROPION-PanTumor01 trial, datopotamab deruxtecan demonstrated promising efficacy and safety among heavily pretreated patients with advanced or metastatic HR-positive, HER2-negative, or...

According to results from the...

05/14/2024

Oncology

News

Addition of Vismodegib to Radiation Therapy Shows Promise Among Patients With Basal Cell Carcinoma

05/10/2024

Stephanie Holland

Results from a prospective, phase 2 study found the addition of induction and concurrent vismodegib to radiation therapy may be considered a therapeutic option for patients with locally advanced, unresectable basal cell carcinoma.

Results from a prospective,...

05/10/2024

Oncology

News

Frontline Rituximab-Bendamustine Followed by Rituximab Maintenance Demonstrates Improved PFS vs R-CHOP Therapy Among Patients With Follicular Lymphoma

05/08/2024

Amber Denham

According to a retrospective study, rituximab-bendamustine followed by rituximab maintenance among patients with previously untreated advanced FL resulted in longer progression-free survival than rituximab, cyclophosphamide, doxorubicin,...

According to a retrospective...

05/08/2024

Oncology

News

Post-Allogeneic Hematopoietic Cell Transplant Gilteritinib Maintenance Demonstrates Benefit for Patients With AML With Detectable FLT3-ITD MRD

05/03/2024

Amber Denham

According to a recent trial, patients with acute myeloid leukemia with FLT3-ITD and measurable residual disease detectable in the peri-transplant period derived benefit from post-transplant gilteritinib, whereas those without detectable MRD...

According to a recent trial,...

05/03/2024

Oncology

News

FDA Approves Tisotumab Vedotin for Patients With Recurrent or Metastatic Cervical Cancer

05/01/2024

Stephanie Holland

Based on results from the phase 3 innovaTV 301 trial, the FDA has approved tisotumab vedotin for patients with recurrent or metastatic cervical cancer who experienced disease progression on or after systemic treatment.

Based on results from the phase...

05/01/2024

Oncology

News

Cabozantinib Shows Promising Activity Among Patients With Progressive, Unresectable Metastatic Phaeochromocytomas and Paragangliomas

04/25/2024

Stephanie Holland

According to results from the phase 2 Natalie trial, cabozantinib showed promising clinical activity among patients with progressive, unresectable metastatic phaeochromocytomas and paragangliomas.

According to results from the...

04/25/2024

Oncology